Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3712-3721

  Graves, Scott S ^a   Dearstyne, Erica ^a   Lin, Yukang ^a   Zuo, Yuting ^a   Sanderson, James ^a   Schultz, Jody ^a   Pantalias, Anastasia ^a   Gray, David ^a   Axworthy, Don ^a   Jones, H Mark ^a   Auditore Hargreaves, Karen ^a  

^a Poniard Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; BIOTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID YTTRIUM 90; GEMCITABINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY CC49; PROTEIN; RADIOACTIVE MATERIAL; RADIOLIGAND; SINGLE CHAIN FV FRAGMENT STREPTAVIDIN FUSION PROTEIN; TAG 72 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER THERAPY; COLON CANCER; COLONY FORMING UNIT; COLONY FORMING UNIT GM; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PRETARGET RADIOIMMUNOTHERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; BROMODEOXYURIDINE; CELL CYCLE; COLONIC NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, GENETIC; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 12444272235     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Schlom, J. Monoclonal antibodies in cancer therapy. In: V. T. Devita, S. Hellman, and S. A. Rosenberg, (eds.), Biological Therapy of Cancer, Ed. 2, pp. 507-521. Philadelphia: JB Lippincott Co., 1995.
2. Knox, S. J., and Meredith, R. F. Clinical radioimmunotherapy. Semin. Radiat. Oncol., 10: 73-93, 2000.
3. Cassidy, J., Newell, D. R., Wedge, S. R., and Cummings, J. Pharmacokinetics of high molecular weight agents. Cancer Surv., 17: 315-341, 1993.
4. DeNardo, G. L., O'Donnell, R. T., Kroger, L. A., Richman, C. M., Goldstein, D. S., Shen, S., and DeNardo, S. J. Strategies for developing effective radioimmunotherapy for solid tumors. Clin. Cancer Res. 5 (Suppl.): 3219s-3223s, 1999.
5. Khazaeli, M. B., Saleh, M. N., Wheeler, R. H., Huster, W. J., Holden, H., Caranno, R., and LoBuglio, A. F. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J. Natl. Cancer Inst. (Bethesda), 80: 937-942, 1988.
6. Reilly, R. M., Sandhu, J., Alvarez-Diez, T. M., Gallinger, S., Kirsh, J., and Stern, H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet., 28: 126-142, 1995.
7. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F-M., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA, 97: 1802-1807, 2000.
8. Theodore L. J., Fritzberg, A. R., Schultz, J. E., and Axworthy, D. B. Evolution of a pretarget radioimmunotherapy regimen. In: P. G. Abrams and A. R. Fritzberg, (eds.), Radioimmunotherapy of Cancer, pp. 195-222. New York: Marcel Dekker, 2000.
9. Weiden, P. L., and Breitz, H. B. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkins lymphoma (NHL). Crit. Rev. Oncol. Hematol. 40:37-51, 2001.
10. Weiden, P. L., Breitz, H. B., Press, O., Appelbaum, J. W., Bryan, J. K., Gaffigan, S., Stone, D., Axworthy, D., Fisher, D., and Reno, J. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial Phase I/II study results. Cancer Biother. Radiopharm., 15: 15-29, 2000.
11. Knox, S. J., Forero-Torres, A., Vose, J. M., Picozzi, V. J., Breitz, H., and Sims, R. B. A Phase I dose optimization study of anti-CD20 Pretarget radioimmunotherapy in patients with relapsed or refractory NHL. Blood 100: 162a, 2002.
12. Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallett, R., Wilbert, S., and Axworthy, D. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res., 60: 6663-6669, 2000.
13. Muraro, R., Kuroki, M., Wunderlick, D., Poole, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., Noguchi, P., and Schlom, J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res., 48: 4588-4596, 1988.
14. Molinolo, A., Simpson, J. F., Thor, A., and Schlom, J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res., 50: 1291-1298, 1990.
15. Mulligan, T., Carrasquillo, J. A., Chung, Y., Milenic, D. E., Schlom, J., Feuerstein, I., Paik, C., Perentesis, P., Reynolds, J., and Curt, G. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer. Res., 1: 1447-1454, 1995.
16. Tempero, M., Leichner, P., Dalrymple, G., Harrison, K., Augustine, S., Schlom, J., Anderson, J., Wisecarver, J., and Colcher, D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J. Clin. Oncol., 15: 1518-1528, 1997.
17. 90yttrium-labeled monoclonal antibody CC49: a Phase I trial. Clin. Cancer Res., 6: 3095-3102, 2000.
18. 131I-labeled monoclonal antibody CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res., 4: 643-651, 1998.
19. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res., 5 (Suppl.): 3254s-3258s, 1999
20. 177Lu-CC49: a Phase I/II study. Gynecol. Oncol., 65: 94-101, 1997.
21. Lawrence, T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W., and Shewach, D. S. Radiosensitization of pancreatic cancer cells by 2′,2′ -difluoro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys., 34: 867-872, 1996.
22. Latz, D., Fleckenstein, K., Eble, M., Blatter, J., Wannenmacher, M., and Weber, K. J. Radiosensitizing potential of gemcitabine (2′,2′ -difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int. J. Radiat. Oncol. Biol. Phys., 41: 875-882, 1998.
23. Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
24. Goshorn, S., Sanderson, J., Axworthy, D., Lin, Y., Hylarides, M., and Schultz, J. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer. Biother. Radiopharm., 16: 109-123, 2001.
25. Wilbur, D. S., Hadley, S. W., Hylarides, M. D., Abrams, P. G., Beaumier, P. L., Morgan, A. C., Reno, J. M., and Fritzberg, A. R. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med., 30: 216-226, 1989.
26. Theodore, L. J., and Axworthy, D. B. Cluster Clearing Agents. PCT Application International Publ. No. W097/46098. Geneva, Switzerland: International Bureau of WIPO, 1997.
27. Tsugita, M., Tsuru, S., Takasaki, T., Shinomiya, N., Kobayashi, S., and Hanyu, F. Flowcytometric measurement of the cell cycle of experimental tumors: some devices for accurate measurement of proliferative activity. Oncology, 48: 343-346, 1991.
28. DeNardo, S. J., Richman, C. M., Kukis, D. L., Shen, S., Lamborn, K. R., Miers, L. A., Kroger, L. A., Perez, E. A., and DeNardo, G. L. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res., 18: 4011-4018, 1998.
29. Ogura, E., Senzaki, H., Yoshizawaka, K., Hioki, K., and Tsubura, A. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res., 18: 3669-3675, 1998.
30. Weiden, P. Pretargeted radioimmunotherapy (PRIT) using an anti, body-streptavidin fusion protein in non-Hodgkin's lymphoma. Leuk, Lymphoma, 43: 1971-1973, 2002.
31. Santos, O., Pant, K. D., Blank, E. W., and Ceriani, R. L. 5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice. J. Nucl. Med., 33: 1530-1534, 1992.
32. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res., 57: 2181-2186, 1997.
33. Shewach, D. S., Hahn, T. M., Chang, E., Hertel, L. W., and Lawrence, T. S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res., 54: 3218-3223, 1994.
34. Lawrence, T. S., Eisbruch, A., McGinn, C. J., Fields, M. T., and Shewach, D. S. Radiosensitization by gemcitabine. Oncology, 13: 55-60, 1999.
35. Fields, M. T., Eisbruch, A., Normolle, D., Orfali, A., Davis, M. A., Pu, A. T., and Lawrence, T. S. Radiosensitization produced in vivo by once- vs. twice weekly 2′,2′-difluroro-2′deoxycytidine (gemcitabine). Int. J. Radiat. Oncol. Biol. Phys., 47: 785-791, 2000.
36. Cardillo, T. M., Blumenthal, R., Ying, Z., and Gold, D. V. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int. J. Cancer, 97: 386-392, 2002.
37. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep., 50: 219-245.
38. Forero-Torres, A., Meredithy, R. F., Shen, S., Breitz, H., Sims, R., and LoBuglio, R. Pretarget radioimmunotherapy with CC49 fusion protein in patients with gastrointestinal (GI) malignancies: preliminary results from a Phase I dose optimization study. Blood, 100: 226b, 2002.